Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
Silke Gillessen
(1, 2)
,
Alberto Bossi
(3, 4)
,
Ian D Davis
(5)
,
Johann de Bono
(6, 7)
,
Karim Fizazi
(3, 8, 9)
,
Nicholas D James
(6)
,
Nicolas Mottet
(10, 11)
,
Neal Shore
(12)
,
Eric Small
(13)
,
Matthew Smith
(14)
,
Christopher Sweeney
(15, 16, 17)
,
Bertrand Tombal
(18)
,
Emmanuel S Antonarakis
(19, 20)
,
Ana M Aparicio
(21)
,
Andrew J Armstrong
(22)
,
Gerhardt Attard
(23)
,
Tomasz M Beer
(24, 25)
,
Himisha Beltran
(15, 16, 17)
,
Anders Bjartell
(26)
,
Pierre Blanchard
(27, 28, 4)
,
Alberto Briganti
(29)
,
Rob G Bristow
(30, 31)
,
Muhammad Bulbul
(32)
,
Orazio Caffo
(33)
,
Daniel Castellano
(34)
,
Elena Castro
(35)
,
Heather H Cheng
(36)
,
Kim N Chi
(37, 38)
,
Simon Chowdhury
(39)
,
Caroline S Clarke
(40)
,
Noel Clarke
(41, 31)
,
Gedske Daugaard
(42)
,
Maria de Santis
(43, 44)
,
Ignacio Duran
(45)
,
Ros Eeles
(7, 6)
,
Eleni Efstathiou
(46)
,
Jason Efstathiou
(14)
,
Onyeanunam Ngozi Ekeke
(47)
,
Christopher P Evans
(48)
,
Stefano Fanti
(49)
,
Felix Y Feng
(50)
,
Valerie Fonteyne
(51)
,
Nicola Fossati
(2)
,
Mark Frydenberg
(52, 5)
,
Daniel George
(22, 53)
,
Martin Gleave
(38)
,
Gwenaelle Gravis
(54, 55)
,
Susan Halabi
(53)
,
Daniel Heinrich
(56)
,
Ken Herrmann
(57, 58, 59)
,
Celestia Higano
(38)
,
Michael S Hofman
(60, 61)
,
Lisa G Horvath
(62, 63)
,
Maha Hussain
(64, 65)
,
Barbara Alicja Jereczek-Fossa
(66, 67)
,
Robert Jones
(68)
,
Ravindran Kanesvaran
(69)
,
Pirkko-Liisa Kellokumpu-Lehtinen
(70, 71)
,
Raja B Khauli
(72, 32)
,
Laurence Klotz
(73, 74)
,
Gero Kramer
(44)
,
Raya Leibowitz
(75)
,
Christopher J Logothetis
(21, 76)
,
Brandon A Mahal
(77, 78)
,
Fernando Maluf
(79)
,
Joaquin Mateo
(80, 81)
,
David Matheson
(82)
,
Niven Mehra
(83)
,
Axel Merseburger
(84)
,
Alicia K Morgans
(16, 17, 15)
,
Michael J Morris
(85)
,
Hind Mrabti
(86)
,
Deborah Mukherji
(87, 32)
,
Declan G Murphy
(88, 61)
,
Vedang Murthy
(89)
,
Paul L Nguyen
(15, 17, 16)
,
William K Oh
(90, 91)
,
Piet Ost
(51)
,
Joe M O'Sullivan
(6, 92)
,
Anwar R Padhani
(93, 6)
,
Carmel Pezaro
(94)
,
Darren M C Poon
(95, 96)
,
Colin C Pritchard
(36)
,
Danny M Rabah
(97, 98)
,
Dana Rathkopf
(85)
,
Robert E Reiter
(99)
,
Mark A Rubin
(100)
,
Charles J Ryan
(101)
,
Fred Saad
(102)
,
Juan Pablo Sade
(103)
,
Oliver A Sartor
(104)
,
Howard I Scher
(85, 105)
,
Nima Sharifi
(106)
,
Iwona Skoneczna
,
Howard Soule
,
Daniel E Spratt
,
Sandy Srinivas
(107)
,
Cora N Sternberg
(108, 109, 110)
,
Thomas Steuber
(111)
,
Hiroyoshi Suzuki
(112)
,
Matthew R Sydes
(40)
,
Mary-Ellen Taplin
(17, 15, 16)
,
Derya Tilki
(111)
,
Levent Türkeri
(113)
,
Fabio Turco
(1)
,
Hiroji Uemura
(114)
,
Hirotsugu Uemura
(115)
,
Yüksel Ürün
(116)
,
Claire L Vale
(40)
,
Inge van Oort
(83)
,
Neha Vapiwala
(117)
,
Jochen Walz
(54)
,
Kosj Yamoah
(118, 119)
,
Dingwei Ye
(120)
,
Evan Y Yu
(121, 122)
,
Almudena Zapatero
(123)
,
Thomas Zilli
(1, 124)
,
Aurelius Omlin
(125)
1
IOSI -
Oncology Institute of Southern Switzerland
2 USI - Università della Svizzera italiana = University of Italian Switzerland
3 IGR - Institut Gustave Roussy
4 Département de radiothérapie [Gustave Roussy]
5 Faculty of Medicine, Nursing and Health Sciences - Monash university [Victoria]
6 The institute of cancer research [London]
7 The Royal Marsden NHS Foundation Trust [London]
8 Université Paris-Saclay
9 Oncologie génito-urinaire
10 Service de Gynécologie Obstétrique [CHRU Besançon]
11 UJM - Université Jean Monnet - Saint-Étienne
12 CURC - Carolina Urologic Research Center [Myrtle Beach, USA]
13 UC San Francisco - University of California [San Francisco]
14 Massachusetts General Hospital [Boston]
15 Dana-Farber Cancer Institute [Boston]
16 Brigham and Women's Hospital [Boston]
17 HMS - Harvard Medical School [Boston]
18 Cliniques Universitaires Saint-Luc [Bruxelles]
19 University of Minnesota Medical School
20 Masonic Cancer Center
21 The University of Texas M.D. Anderson Cancer Center [Houston]
22 Duke Cancer Institute Durham, North Carolina, USA.
23 UCLH - University College London Hospitals
24 Knight Cancer Institute
25 UP - University of Portland
26 Skane University Hospital [Lund]
27 CESP - Centre de recherche en épidémiologie et santé des populations
28 U1018 (Équipe 2) - Oncostat
29 San Raffaele Scientific Institute
30 University of Manchester [Manchester]
31 The Christie NHS Foundation Trust [Manchester, Royaume-Uni]
32 AUB - American University of Beirut Faculty of Medicine and Medical Center
33 Medical Oncology, Santa Chiara Hospital, Trento, Italy
34 Hospital Universitario 12 de Octubre [Madrid]
35 IBIMA Plataforma BIONAND - Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina = Biomedical Research Institute of Málaga and Nanomedicine Platform
36 University of Washington [Seattle]
37 VPC - Vancouver Prostate Centre [Vancouver General Hospital]
38 UBC - University of British Columbia [Canada]
39 Guy's and St Thomas' NHS Foundation Trust
40 UCL - University College of London [London]
41 Salford Royal NHS Foundation Trust [Salford, UK]
42 Copenhagen University Hospital
43 Charité - UniversitätsMedizin = Berlin University Medicine
44 Medizinische Universität Wien = Medical University of Vienna
45 Hospital Universitario Marqués de Valdecilla [Santander]
46 The Houston Methodist Research Institute
47 University of Port Harcourt
48 UC Davis - University of California [Davis]
49 AOUB - IRCCS Azienda Ospedaliero-Universitaria di Bologna
50 UC - University of California
51 Ghent University Hospital
52 Monash University [Melbourne]
53 Duke University [Durham]
54 IPC - Institut Paoli-Calmettes
55 AMU SMPM MED - Aix-Marseille Université - École de médecine
56 IHT - Innlandet Hospital Trust [Gjøvik]
57 Universität Duisburg-Essen = University of Duisburg-Essen [Essen]
58 DKTK - German Cancer Consortium [Heidelberg]
59 AöR - University Hospital Essen
60 Peter MacCallum Cancer Centre
61 University of Melbourne
62 Garvan Institute of medical research
63 The University of Sydney
64 Northwestern University [Evanston]
65 Robert H. Lurie Comprehensive Cancer Center
66 UNIMI - Università degli Studi di Milano = University of Milan
67 EIO - European Institute of Oncology IRCCS [Milan, Italy]
68 University of Glasgow
69 NCCS - National Cancer Centre Singapore
70 Tampere University Hospital
71 University of Tampere [Finland]
72 Naef K. Basile Cancer Institute (NKBCI), Breast Center of Excellence
73 Sunnybrook - Sunnybrook Health Sciences Centre [Toronto]
74 University of Toronto
75 TAU - Tel Aviv University
76 University of Athens Medical School [Athens]
77 University of Miami
78 S3C - Sylvester Comprehensive Cancer Center [Miami, FL, USA]
79 Hospital Israelita Albert Einstein [São Paulo, Brazil]
80 Vall d'Hebron University Hospital [Barcelona]
81 Vall d'Hebron Institute of Oncology (VHIO)
82 University of Wolverhampton
83 Radboud University Medical Center [Nijmegen]
84 University Hospital Schleswig-Holstein [Kiel, Germany]
85 Memorial Sloane Kettering Cancer Center [New York]
86 LERMA, Mohammadia School of Engineering, University Mohamed V, Rabat, Morocco
87 CMC - Clemenceau Medical Center
88 Peter MacCallum Cancer Centre [Melbourne, Australie]
89 Tata Memorial Centre
90 MSSM - Icahn School of Medicine at Mount Sinai [New York]
91 The Tisch Cancer Institute
92 Belfast City Hospital
93 MV2C - Mount Vernon Cancer Centre [Northwood, UK]
94 Sheffield Teaching Hospitals NHS Foundation Trust [Sheffield, Royaume-Uni]
95 HKSH - Hong Kong Sanatorium and Hospital [Hong Kong]
96 CUHK - The Chinese University of Hong Kong [Hong Kong]
97 KSU - King Saud University [Riyadh]
98 KFSHRC - King Faisal Specialist Hospital and Resarch Centre [Riyadh, Saudi Arabia]
99 UCLA - University of California [Los Angeles]
100 UNIBE - Universität Bern = University of Bern = Université de Berne
101 UMC - University of Minnesota [Crookston]
102 CHUM - Centre Hospitalier de l'Université de Montréal
103 IAF - Instituto Alexander Fleming [Buenos Aires, Argentina]
104 Tulane University
105 Weill Medical College of Cornell University [New York]
106 Cleveland Clinic
107 Stanford University
108 Sandra and Edward Meyer Cancer Center [New-York]
109 New York Presbyterian Hospital
110 Weill Cornell Medicine [Cornell University]
111 University Hospital Hamburg-Eppendorf
112 Toho University
113 ACU - Acibadem Mehmet Ali Aydınlar University
114 YCU - Yokohama City University
115 Kindai University
116 Ankara University School of Medicine [Turkey]
117 University of Pennsylvania
118 H. Lee Moffitt Cancer Center and Research Institute
119 USF - University of South Florida [Tampa]
120 Shanghai Medical College, Fundan University [Shanghai China]
121 University of Washington [Tacoma]
122 FHCRC - Fred Hutchinson Cancer Research Center [Seattle]
123 Hospital Universitario de La Princesa
124 UNIGE - Université de Genève = University of Geneva
125 UZH - Universität Zürich [Zürich] = University of Zurich
2 USI - Università della Svizzera italiana = University of Italian Switzerland
3 IGR - Institut Gustave Roussy
4 Département de radiothérapie [Gustave Roussy]
5 Faculty of Medicine, Nursing and Health Sciences - Monash university [Victoria]
6 The institute of cancer research [London]
7 The Royal Marsden NHS Foundation Trust [London]
8 Université Paris-Saclay
9 Oncologie génito-urinaire
10 Service de Gynécologie Obstétrique [CHRU Besançon]
11 UJM - Université Jean Monnet - Saint-Étienne
12 CURC - Carolina Urologic Research Center [Myrtle Beach, USA]
13 UC San Francisco - University of California [San Francisco]
14 Massachusetts General Hospital [Boston]
15 Dana-Farber Cancer Institute [Boston]
16 Brigham and Women's Hospital [Boston]
17 HMS - Harvard Medical School [Boston]
18 Cliniques Universitaires Saint-Luc [Bruxelles]
19 University of Minnesota Medical School
20 Masonic Cancer Center
21 The University of Texas M.D. Anderson Cancer Center [Houston]
22 Duke Cancer Institute Durham, North Carolina, USA.
23 UCLH - University College London Hospitals
24 Knight Cancer Institute
25 UP - University of Portland
26 Skane University Hospital [Lund]
27 CESP - Centre de recherche en épidémiologie et santé des populations
28 U1018 (Équipe 2) - Oncostat
29 San Raffaele Scientific Institute
30 University of Manchester [Manchester]
31 The Christie NHS Foundation Trust [Manchester, Royaume-Uni]
32 AUB - American University of Beirut Faculty of Medicine and Medical Center
33 Medical Oncology, Santa Chiara Hospital, Trento, Italy
34 Hospital Universitario 12 de Octubre [Madrid]
35 IBIMA Plataforma BIONAND - Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina = Biomedical Research Institute of Málaga and Nanomedicine Platform
36 University of Washington [Seattle]
37 VPC - Vancouver Prostate Centre [Vancouver General Hospital]
38 UBC - University of British Columbia [Canada]
39 Guy's and St Thomas' NHS Foundation Trust
40 UCL - University College of London [London]
41 Salford Royal NHS Foundation Trust [Salford, UK]
42 Copenhagen University Hospital
43 Charité - UniversitätsMedizin = Berlin University Medicine
44 Medizinische Universität Wien = Medical University of Vienna
45 Hospital Universitario Marqués de Valdecilla [Santander]
46 The Houston Methodist Research Institute
47 University of Port Harcourt
48 UC Davis - University of California [Davis]
49 AOUB - IRCCS Azienda Ospedaliero-Universitaria di Bologna
50 UC - University of California
51 Ghent University Hospital
52 Monash University [Melbourne]
53 Duke University [Durham]
54 IPC - Institut Paoli-Calmettes
55 AMU SMPM MED - Aix-Marseille Université - École de médecine
56 IHT - Innlandet Hospital Trust [Gjøvik]
57 Universität Duisburg-Essen = University of Duisburg-Essen [Essen]
58 DKTK - German Cancer Consortium [Heidelberg]
59 AöR - University Hospital Essen
60 Peter MacCallum Cancer Centre
61 University of Melbourne
62 Garvan Institute of medical research
63 The University of Sydney
64 Northwestern University [Evanston]
65 Robert H. Lurie Comprehensive Cancer Center
66 UNIMI - Università degli Studi di Milano = University of Milan
67 EIO - European Institute of Oncology IRCCS [Milan, Italy]
68 University of Glasgow
69 NCCS - National Cancer Centre Singapore
70 Tampere University Hospital
71 University of Tampere [Finland]
72 Naef K. Basile Cancer Institute (NKBCI), Breast Center of Excellence
73 Sunnybrook - Sunnybrook Health Sciences Centre [Toronto]
74 University of Toronto
75 TAU - Tel Aviv University
76 University of Athens Medical School [Athens]
77 University of Miami
78 S3C - Sylvester Comprehensive Cancer Center [Miami, FL, USA]
79 Hospital Israelita Albert Einstein [São Paulo, Brazil]
80 Vall d'Hebron University Hospital [Barcelona]
81 Vall d'Hebron Institute of Oncology (VHIO)
82 University of Wolverhampton
83 Radboud University Medical Center [Nijmegen]
84 University Hospital Schleswig-Holstein [Kiel, Germany]
85 Memorial Sloane Kettering Cancer Center [New York]
86 LERMA, Mohammadia School of Engineering, University Mohamed V, Rabat, Morocco
87 CMC - Clemenceau Medical Center
88 Peter MacCallum Cancer Centre [Melbourne, Australie]
89 Tata Memorial Centre
90 MSSM - Icahn School of Medicine at Mount Sinai [New York]
91 The Tisch Cancer Institute
92 Belfast City Hospital
93 MV2C - Mount Vernon Cancer Centre [Northwood, UK]
94 Sheffield Teaching Hospitals NHS Foundation Trust [Sheffield, Royaume-Uni]
95 HKSH - Hong Kong Sanatorium and Hospital [Hong Kong]
96 CUHK - The Chinese University of Hong Kong [Hong Kong]
97 KSU - King Saud University [Riyadh]
98 KFSHRC - King Faisal Specialist Hospital and Resarch Centre [Riyadh, Saudi Arabia]
99 UCLA - University of California [Los Angeles]
100 UNIBE - Universität Bern = University of Bern = Université de Berne
101 UMC - University of Minnesota [Crookston]
102 CHUM - Centre Hospitalier de l'Université de Montréal
103 IAF - Instituto Alexander Fleming [Buenos Aires, Argentina]
104 Tulane University
105 Weill Medical College of Cornell University [New York]
106 Cleveland Clinic
107 Stanford University
108 Sandra and Edward Meyer Cancer Center [New-York]
109 New York Presbyterian Hospital
110 Weill Cornell Medicine [Cornell University]
111 University Hospital Hamburg-Eppendorf
112 Toho University
113 ACU - Acibadem Mehmet Ali Aydınlar University
114 YCU - Yokohama City University
115 Kindai University
116 Ankara University School of Medicine [Turkey]
117 University of Pennsylvania
118 H. Lee Moffitt Cancer Center and Research Institute
119 USF - University of South Florida [Tampa]
120 Shanghai Medical College, Fundan University [Shanghai China]
121 University of Washington [Tacoma]
122 FHCRC - Fred Hutchinson Cancer Research Center [Seattle]
123 Hospital Universitario de La Princesa
124 UNIGE - Université de Genève = University of Geneva
125 UZH - Universität Zürich [Zürich] = University of Zurich
Karim Fizazi
- Fonction : Auteur
Pierre Blanchard
- Fonction : Auteur
- PersonId : 1038224
- IdHAL : pierre-blanchard-hal
- ORCID : 0000-0003-4785-3409
Iwona Skoneczna
- Fonction : Auteur
Howard Soule
- Fonction : Auteur
Daniel E Spratt
- Fonction : Auteur
Résumé
Background: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management.
Objective: To present consensus voting results for select questions from APCCC 2022.
Design, setting, and participants: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members ("panellists") who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1-3.
Outcome measurements and statistical analysis: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement.
Results and limitations: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis.
Conclusions: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers prioritise areas for future research. Diagnostic and treatment decisions should always be individualised based on patient and cancer characteristics (disease extent and location, treatment history, comorbidities, and patient preferences) and should incorporate current and emerging clinical evidence, therapeutic guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2022 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials.
Patient summary: The Advanced Prostate Cancer Consensus Conference (APCCC) provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference aims to share the knowledge of international experts in prostate cancer with health care providers and patients worldwide. At each APCCC, a panel of physician experts vote in response to multiple-choice questions about their clinical opinions and approaches to managing advanced prostate cancer. This report presents voting results for the subset of questions pertaining to intermediate- and high-risk and locally advanced prostate cancer, biochemical relapse after definitive treatment, advanced (next-generation) imaging, and management of side effects caused by hormonal therapies. The results provide a practical guide to help clinicians and patients discuss treatment options as part of shared multidisciplinary decision-making. The findings may be especially useful when there is little or no high-level evidence to guide treatment decisions.
| Origine | Publication financée par une institution |
|---|---|
| Licence |
